Trials / Completed
CompletedNCT00400660
A First Time In Human Study To Assess The Compound GSK615915
First Time in Human, Single Dose and Repeat Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK615915
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more stable drug suspension, this in turn will produce a consistent dose of drug being delivered with each puff.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK615915A | GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler. |
| DRUG | Placebo | Subjects will also receive placebo inhaler. |
Timeline
- Start date
- 2005-11-23
- Primary completion
- 2006-07-03
- Completion
- 2006-07-03
- First posted
- 2006-11-17
- Last updated
- 2017-09-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00400660. Inclusion in this directory is not an endorsement.